ClinicalTrials.gg

TargetBeta

GPRC5D

G protein-coupled receptor class C group 5 member D · G protein-coupled receptors, Class C orphans

11 programs in company-led studies act on GPRC5D, from 9 companies: 5 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
ramantamigJohnson & Johnsonphase 377 runningCD3E, TNFRSF17a judged reading
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 344 runningCD3E, TNFRSF17NCIt
QLS4131ruleQilu Pharmaceuticalphase 333 runningCD3Ethe studies' text
arlocabtagene autoleucelBristol-Myers Squibbphase 332 running–a judged reading
QLS32015ruleQilu Pharmaceuticalphase 322 runningCD3Ethe studies' text
MBS314 for InjectionruleBeijing Mabworks Biotechphase 211 runningCD3Ethe studies' text
REGN17372ruleRegeneron Pharmaceuticalsphase 211 runningCD28, CD3Ethe studies' text
vemzatatug vedotinAstraZenecaphase 211 running–a judged reading
Anti-GPRC5D Monoclonal Antibody SAR446523Sanofiphase 111 running–the company's pipeline
TQB2029Sino Biopharmaceuticalphase 111 runningCD3Ethe company's pipeline
tunlucabtagene autoleucelBristol-Myers Squibbphase 111 runningTNFRSF17a judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.